Selected outcome
a full approval or an accelerated approval
73%
a full approval or an accelerated approval · 73%
Stored quote · checking the venue
- Scheduled end
- Dec 31, 2026 ET
- Resolution source
- AppliedXL (opens in a new tab)
Price
a full approval or an accelerated approval
Loading price history.
Markets
- a full approval or an accelerated approval
What will the FDA's decision be on Saroglitazar by Zydus Therapeutics in 2026?
73%
Open · ~$0 24h · ~$994 vol
Bid 69¢ · Ask 76¢
Event statistics
How this resolves
One winner.
- Scheduled end
- Dec 31, 2026 ET
- Resolution source
- Trading
- Closed
- In review
- Resolved
Rules text
If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.